| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | CENPR, NRIF3, TAP20, CENP-R, HSU37139 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human ITGB3BP |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4条关于 **ITGB3BP抗体** 的模拟参考文献(示例为假设性文献，仅供参考格式和内容方向)：
---
1. **文献名称**: *"ITGB3BP promotes tumor angiogenesis and metastasis via integrin β3 signaling"*
**作者**: Zhang, Y., et al. (2020)
**摘要**: 本研究通过抗ITGB3BP抗体的阻断实验，发现ITGB3BP通过结合整合素β3增强肿瘤细胞的黏附和迁移能力，并激活下游FAK/PI3K通路，促进血管生成和癌症转移。
2. **文献名称**: *"Autoantibodies against ITGB3BP in systemic lupus erythematosus: diagnostic and pathogenic implications"*
**作者**: Lee, S., & Kim, H. (2019)
**摘要**: 首次报道系统性红斑狼疮(SLE)患者血清中存在抗ITGB3BP自身抗体，提示其可能通过干扰细胞外基质相互作用参与自身免疫反应，并可能作为SLE的新型生物标志物。
3. **文献名称**: *"ITGB3BP regulates NF-κB activation through interaction with TRAF2 in inflammatory responses"*
**作者**: Wang, X., et al. (2021)
**摘要**: 利用ITGB3BP特异性抗体进行免疫共沉淀实验，证明ITGB3BP通过与TRAF2蛋白结合调控NF-κB信号通路，影响巨噬细胞的炎症因子分泌。
4. **文献名称**: *"Development of a high-affinity monoclonal antibody for ITGB3BP and its application in ovarian cancer diagnostics"*
**作者**: Gupta, R., et al. (2018)
**摘要**: 开发了一种新型抗ITGB3BP单克隆抗体，验证其在卵巢癌组织中的高表达，并证明其可用于临床样本的免疫组化检测，与患者预后不良相关。
---
**注**：以上文献为模拟示例，实际研究请通过学术数据库(如PubMed、Web of Science)检索真实文献。
ITGB3BP (Integrin Beta 3 Binding Protein), also known as TAP20 or NRIF3. is a multifunctional protein involved in cell adhesion, signaling, and transcriptional regulation. It interacts with integrin β3 subunits, modulating integrin-mediated processes like cell migration, proliferation, and survival. Structurally, it contains an N-terminal nuclear localization signal, a central coiled-coil domain, and a C-terminal integrin-binding region, enabling its dual roles in both cytoplasmic/nuclear compartments.
ITGB3BP regulates transcriptional activity by interacting with nuclear receptors (e.g., thyroid hormone receptor) and transcription factors, influencing pathways such as NF-κB and MAPK. It also participates in DNA damage response and stress signaling. Dysregulation of ITGB3BP is linked to cancer progression, cardiovascular diseases, and immune disorders, highlighting its potential as a therapeutic target.
Antibodies targeting ITGB3BP are essential tools for studying its expression, localization, and function. They are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate its role in cellular processes and disease models. These antibodies are typically validated for specificity using knockout controls or siRNA knockdown. Commercial ITGB3BP antibodies are often raised against recombinant protein fragments or synthetic peptides corresponding to conserved regions. Researchers utilize them to explore ITGB3BP's involvement in tumor metastasis, angiogenesis, and drug resistance, providing insights into its clinical relevance.
×
